title: Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.
abstract: Electronegative LDL, a charge-modified LDL (cm-LDL) subfraction that is more negatively charged than normal LDL, has been shown to be inflammatory. We previously showed that pravastatin and simvastatin reduced the electronegative LDL subfraction, fast-migrating LDL (fLDL), as analyzed by capillary isotachophoresis (cITP). The present study examined the effects of rosuvastatin on the more electronegative LDL subfraction, very-fast-migrating LDL (vfLDL), and small, dense charge-modified LDL (sd-cm-LDL) subfractions. Patients with hypercholesterolemia or those who were being treated with statins (n = 81) were treated with or switched to 2.5 mg/d rosuvastatin for 3 months. Rosuvastatin treatment effectively reduced cITP cm-LDL subfractions of LDL (vfLDL and fLDL) or sdLDL (sd-vfLDL and sd-fLDL), which were closely related to each other but were different from the normal subfraction of LDL [slow-migrating LDL (sLDL)] or sdLDL (sd-sLDL) in their relation to the levels of remnant-like particle cholesterol (RLP-C), apolipoprotein (apo) C-II, and apoE. The percent changes in cm-LDL or sd-cm-LDL caused by rosuvastatin were correlated with those in the particle concentrations of LDL or sdLDL measured as LDL-apoB or sdLDL-apoB and the levels of HDL-C, RLP-C, apoC-II, and apoE. In conclusion, rosuvastatin effectively reduced both the vfLDL subfraction and sd-cm-LDL subfractions as analyzed by cITP.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Akira
authors.initials: A
authors.lastname: Matsunaga
authors.forename: David L
authors.initials: DL
authors.lastname: Rainwater
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Miura
authors.forename: Keita
authors.initials: K
authors.lastname: Noda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Uehara
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shirai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ogawa
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D001053:Apolipoproteins / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000150:complications; D019075:Electrophoresis, Capillary; D005260:Female; D005464:Fluorobenzenes / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications; D007249:Inflammation / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000494:pharmacology*; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D015415:Biomarkers; D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; C112017:remnant-like particle cholesterol; D000068718:Rosuvastatin Calcium; D002784:Cholesterol